Schedule of significant expense categories regularly reviewed by the CODM |
| | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | (in thousands) | | | | | | | | | | | | | Partnership revenue | | $ | 667 | | $ | 628 | | $ | 1,399 | | $ | 1,125 | Product revenue | | | 169 | | | 150 | | | 305 | | | 273 | Expenses: | | | | | | | | | | | | | Cost of product revenues | | | 46 | | | 44 | | | 90 | | | 78 | Non-clinical development costs | | | 4,607 | | | 4,648 | | | 9,072 | | | 7,947 | Clinical development costs | | | 2,633 | | | 1,504 | | | 5,575 | | | 2,547 | Personnel and consulting costs | | | 7,002 | | | 5,913 | | | 13,666 | | | 11,407 | Stock-based compensation | | | 3,250 | | | 2,761 | | | 6,215 | | | 5,349 | Depreciation expense | | | 81 | | | 74 | | | 164 | | | 148 | Other segment expenses(1) | | | 2,544 | | | 2,716 | | | 5,170 | | | 5,283 | Interest income (expense), net | | | 36 | | | (902) | | | (130) | | | (1,918) | Net Loss | | $ | (19,363) | | $ | (15,980) | | $ | (38,118) | | $ | (29,443) |
1Other segment expenses primarily include general and administrative costs not presented in other line items.
|